198 related articles for article (PubMed ID: 25729731)
1. Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.
Zhang S; Wilson D; Czader M
Ann Lab Med; 2015 Mar; 35(2):254-6. PubMed ID: 25729731
[No Abstract] [Full Text] [Related]
2. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
Jaradat JM; Potluri A; Bilodeau EA
Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
[TBL] [Abstract][Full Text] [Related]
3. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
5. [Significance and application of c-myc in diffuse large B-cell lymphoma].
Huang WT; Lü N; Guo L
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
[No Abstract] [Full Text] [Related]
6. [Primary cutaneous follicle centre lymphoma: report of a case].
Rong YF; He LM; Zhang YS; Feng YZ
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):769-70. PubMed ID: 24447559
[No Abstract] [Full Text] [Related]
7. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological and molecular genetic characteristics of childhood diffuse large B cell lymphoma].
Huang H; Yang WP; Xu HY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):209-11. PubMed ID: 22780976
[No Abstract] [Full Text] [Related]
9. [Successful treatment with dose-adjusted EPOCH-R for triple-hit lymphoma having BCL2, BCL6 and MYC translocations].
Hashimoto A; Fujimi A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Matsumoto T; Shibata T; Hamaguchi K; Kamihara Y; Iwasaki S; Kato J
Rinsho Ketsueki; 2015 Jul; 56(7):905-10. PubMed ID: 26256929
[TBL] [Abstract][Full Text] [Related]
10. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
[TBL] [Abstract][Full Text] [Related]
11. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Frick M; Dörken B; Lenz G
Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
13. CD56-positive diffuse large B-cell lymphoma/leukemia with
Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
[TBL] [Abstract][Full Text] [Related]
14. Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
Frosch ZAK; Landsburg DJ
J Clin Oncol; 2020 Jun; 38(18):2014-2017. PubMed ID: 32243222
[No Abstract] [Full Text] [Related]
15. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
16. Large solitary splenic diffuse large B cell lymphoma in a hepatitis C virus-infected patient.
Kedmi M; Fridlander T; Ilan Y; Shibolet O
Isr Med Assoc J; 2005 May; 7(5):346-7. PubMed ID: 15909475
[No Abstract] [Full Text] [Related]
17. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
18. [Spindle cell variants of diffuse large B cell lymphoma: report of 2 cases].
Wang JC; Shi DR; Fu XL; Lu CL; Lu WP
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):55-6. PubMed ID: 15796885
[No Abstract] [Full Text] [Related]
19. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
Nascimento AF; Winters GL; Pinkus GS
Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189
[TBL] [Abstract][Full Text] [Related]
20. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
